Moderna’s mRNA RSV vaccine delivers impressive Phase 3 trial results
Moderna has announced promising results from its Phase 3 trial testing an mRNA vaccine for RSV in older adults. Data indicates the vaccine is nearly 84% effective at preventing moderate disease and the company expects to file for FDA approval this year. Source of Article